Advisers to the Food and Drug Administration voted to back shots made by Novavax for U.S. adults. If the FDA ultimately agrees, Novavax’s option could become the nation’s fourth COVID-19 vaccine.
https://www.nj.com/coronavirus/2022/06/fda-advisers-back-novavax-covid-vaccine-as-4th-us-option.html